NEXAVAR is contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of NEXAVAR. NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Cardiac ischemia and/or myocardial infarction may occur. The incidence of cardiac ischemia/infarction was 2.9% in NEXAVAR-treated patients vs 0.4% for placebo-treated patients. continue reading below »
Nexavar was the first oral systemic therapy approved for the treatment of patients with advanced RCC. The efficacy of Nexavar was proven in the largest phase 3 study for advanced RCC.1 Results were confirmed in large, community-based, expanded-access programs in North America and Europe—providing real-world results consistent with TARGET.2,3*You may help your patients with advanced RCC by including Nexavar in your treatment plan.
References: 1. Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312-3318. 2. Stadler WM, Figlin RA, McDermott DF, et al; ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010;116(5):1272-1280. 3. Beck J, Procopio G, Negrier S, et al. Final efficacy analysis of a large, open-label, noncomparative study of sorafenib in European patients with advanced RCC (EU-ARCCS) [poster]. Presented at 34th ESMO Annual Congress; September 20-24, 2009; Berlin, Germany.
*TARGET (Treatment Approaches in Renal Cancer Global Evaluation Trial): A randomized, double-blind, placebo-controlled, multicenter, phase 3 study in patients with advanced RCC who had received 1 prior systemic therapy (N=903).